• Kryptowährungen
  • Prognosemärkte
  • Nachrichten
  • Agentic Trading
  • Artikel
  • Ligen

Suche Kryptowährungen

Trendende Kryptowährungen

CoinRithm

Firma

Rechtsträger
Bees-x Limited
Unternehmensnummer
13308136
Eingetragen in
England and Wales
Eingetragener Sitz
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm ist ein Informations- und Recherchedienst der Bees-x Limited. Das Unternehmen ist von der Financial Conduct Authority (FCA) nicht zur Ausübung regulierter Tätigkeiten zugelassen, und nichts auf dieser Website stellt Finanzberatung dar.

Entdecken

KryptowährungenPrognosemärkteNachrichtenArtikelAgent ArenaLigen

Funktionen

DashboardProbespielAgentic TradingPortfolioBeobachtungslisteEinstellungen

Firma

Über UnsMethodikFür den UnterrichtNutzungsbedingungenDatenschutzrichtlinieCookie-RichtlinieHaftungsausschluss

Support

KundendienstFAQEntwickler-KitMCP-Dokumentation

Soziale Medien

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Alle Rechte vorbehalten.
Jetzt bei Google PlayLaden im App Store
  • Start
  • MärktePrognosemärkte
  • Nachrichten
  • Dashboard
  1. Prognosemärkte
  2. Health & Medicine
  3. Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)
Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

Phase 3 Result: Sublingual Minoxidil by Samson Clinical Operations (June 2026)

1.0% (24h)One-OffHealth & MedicineWissenschaft12T
KalshiKalshiVerfügbarkeit prüfenKYC erforderlich2% Gebühr
Aktuelle implizite Wahrscheinlichkeit
Success
Success 17%-1.0%
Führend unter 5 Optionen
Marktqualitat

28 / 100

Niedrige Qualität
24h-Volumen

1 €

Liquidität

5,4 €

Niedrige Liquidität
Geld / Brief

16.0% / 23.0%

Spread

43.8%

Breiter Spread
Marktdaten

Aktualisiert vor 3 Minuten

10. Juni 26, 0:001. Juli 26, 3:59

Trends

Ergebnis24hWahrscheinlichkeit

Gewähltes Ergebnis

Success17%

Regeln

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.

Verwandte Märkte

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,6 €
Ja: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Delivery Ritalin exists in one year?

432,8 €
Ja: 7.5%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will there be a cure for schizophrenia before 2032?

432,8 €
Ja: 11.8%Manifold MarketsMANIFOLD MARKETS
When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

0,9 €
before December: 54%KalshiKALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

0,1 €
before October: 42%KalshiKALSHI
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

0 €
before September: 46%KalshiKALSHI

In diesen Themen aktiv

BitcoinBTC$63,931.19-2.89%EthereumETH$1,734.84-3.27%SolanaSOL$71.19-3.46%DogecoinDOGE$0.0847-3.23%XRPXRP$1.17-3.56%BNBBNB$592.24-2.19%

Verwandte Nachrichten

NVIDIA BioNeMo Enables LoRA Fine-Tuning for Biotech ModelsBlockchain.NewsEthereum Researcher: Quantum-Proof Accounts Possible for $0.07Blockchain.NewsIBM Launches ffsim to Accelerate Fermionic Circuit SimulationsBlockchain.NewsAnthropic Targets AI-Driven Biology with gget Virus ToolBlockchain.NewsAnthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.NewsChainalysis reveals $100 million peptide market built on cryptoCrypto News

Regeln

If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Success results in June 2026, the market resolves to Yes.

Kalshi
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Mixed results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Failure results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports Ambiguous results in June 2026, the market resolves to Yes.
  • If the Phase 3 trial SAM-002 of Sublingual Minoxidil by Samson Clinical Operations reports No Results results in June 2026, the market resolves to Yes.